文献速递神经免疫

2013至2017年Medicare Part D中神经科医生处方药支付的五年趋势

Five-Year Trends in Payments for Neurologist-Prescribed Drugs in Medicare Part D.
PubMed 文献 · Neurology · 2021-03-10

该研究回顾分析了2013至2017年Medicare Part D处方索赔数据,纳入神经科医生开具的520种药物。结果显示索赔数量仅增加7.6%,但总支付额增长50.4%;经通胀调整后,通用名药支付仅增0.6%,而仅品牌名药和虽有仿制药可用的品牌名药分别显著增长42.4%和45.0%。

要点

  • 经通胀调整后,品牌名药支付增幅显著高于通用名药。
  • 神经免疫/多发性硬化药物占总支付额超过50%,但仅占索赔的4.3%。
  • 总支付额增长50.4%远超索赔数量7.6%的增幅。

核心结论

  • 2013至2017年,Medicare Part D中神经科医生处方的品牌名药支付持续增长且远超通胀,通用名药支付基本持平。

研究设计与样本

  • 对2013至2017年Medicare Part D处方者公共使用文件进行回顾性分析,纳入神经科医生开具且五年均存在的520种药物。

主要发现

  • 共纳入520种药物,包括322种通用名药、61种仅品牌名药和137种虽有仿制药可用的品牌名药,涉及90,716,536次索赔,支付总额26,654,750,720美元。
  • 索赔数量从2013至2017年增长7.6%,总支付额增长50.4%。
  • 经通胀调整后,通用名药每索赔支付增长0.6%,仅品牌名药增长42.4%,虽有仿制药可用的品牌名药增长45.0%(p趋势<0.001)。
  • 通用名药索赔占比从81.9%升至88.0%,仅品牌名药从4.9%升至6.2%,虽有仿制药可用的品牌名药从13.3%降至5.8%。
  • 神经免疫/多发性硬化药物占总支付额超过50%,但仅占索赔的4.3%。

临床怎么用

  • 提示神经科医生和医保管理者需关注品牌名药支出增长对神经科医保预算的压力。
  • 可考虑在临床允许时优先选用通用名药以控制费用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether there was an increase in payments for neurologist-prescribed drugs, we performed a retrospective analysis of prescription claims in the Medicare Part D Prescriber Public Use Files from 2013 to 2017. METHODS: We included claims prescribed by providers with the taxonomy "neurology" and included drugs present in all 5 years. Drugs were designated in 2013 as generic (GEN), brand name only (BNO), and brand name prescribed even though a generic equivalent is available (BNGE). To observe payment trends, the percentage change in the per claim payment was compared between drug classes. RESULTS: We included 520 drugs, of which 322 were GEN, 61 were BNO, and 137 were BNGE, representing 90,716,536 claims and generating payments of $26,654,750,720. While the number of claims from 2013 to 2017 increased only 7.6%, the total payment increased 50.4%. Adjusted for inflation, claim payments for GEN drug increased 0.6%, compared to significant increases in BNO and BNGE drugs of 42.4% and 45.0% (p trend < 0.001). The percentage of overall GEN claims increased from 81.9% to 88.0%, BNO increased from 4.9% to 6.2%, and BNGE decreased from 13.3% to 5.8%. Neuroimmunology/multiple sclerosis drugs represented >50% of the total payments despite being only 4.3% of claims. CONCLUSIONS: Payments for neurologist-prescribed brand name, but not generic, drugs in Medicare Part D increased consistently and well above inflation from 2013 to 2017. Unless the overall trend stabilizes or is reversed or high cost-to-claim drugs are addressed, this trend will place an increasing burden on the neurologic Medicare budget.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. de Havenon A, Delic A, Dehoney S, et al. Five-Year Trends in Payments for Neurologist-Prescribed Drugs in Medicare Part D. Neurology. 2021. PMID: 33692164. doi:10.1212/WNL.0000000000011712

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。